Literature DB >> 10885776

Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies.

J W Erickson1, S V Gulnik, M Markowitz.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10885776

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  20 in total

1.  Classification of HIV protease inhibitors on the basis of their antiviral potency using radial basis function neural networks.

Authors:  S J Patankar; P C Jurs
Journal:  J Comput Aided Mol Des       Date:  2003 Feb-Apr       Impact factor: 3.686

2.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

3.  Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.

Authors:  Yunfeng Tie; Peter I Boross; Yuan-Fang Wang; Laquasha Gaddis; Fengling Liu; Xianfeng Chen; Jozsef Tozser; Robert W Harrison; Irene T Weber
Journal:  FEBS J       Date:  2005-10       Impact factor: 5.542

4.  The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.

Authors:  Robert W Shafer; Rami Kantor; Matthew J Gonzales
Journal:  AIDS Rev       Date:  2000       Impact factor: 2.500

5.  Human immunodeficiency virus type 1 group m protease in cameroon: genetic diversity and protease inhibitor mutational features.

Authors:  Peter N Fonjungo; Eitel N Mpoudi; Judith N Torimiro; George A Alemnji; Laura T Eno; Esther J Lyonga; John N Nkengasong; Renu B Lal; Mark Rayfield; Marcia L Kalish; Thomas M Folks; Danuta Pieniazek
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 6.  HIV disease and advanced age: an increasing therapeutic challenge.

Authors:  Roberto Manfredi
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 7.  The role of protease inhibitor therapy in children with HIV infection.

Authors:  Patrick J Gavin; Ram Yogev
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

8.  Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay.

Authors:  Amit Kapoor; Morris Jones; R W Shafer; Soo-Yon Rhee; Powel Kazanjian; Eric L Delwart
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

9.  Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.

Authors:  Michael F Maguire; Rosario Guinea; Philip Griffin; Sarah Macmanus; Robert C Elston; Josie Wolfram; Naomi Richards; Mary H Hanlon; David J T Porter; Terri Wrin; Neil Parkin; Margaret Tisdale; Eric Furfine; Chris Petropoulos; B Wendy Snowden; Jörg-Peter Kleim
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.

Authors:  Sarah K Ho; Roxana M Coman; Joshua C Bunger; Stephanie L Rose; Patricia O'Brien; Isabel Munoz; Ben M Dunn; John W Sleasman; Maureen M Goodenow
Journal:  Virology       Date:  2008-07-02       Impact factor: 3.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.